RGC Relative Valuation
RGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGC is overvalued; if below, it's undervalued.
Historical Valuation
Regencell Bioscience Holdings Ltd (RGC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：52.88
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Regencell Bioscience Holdings Ltd. (RGC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Regencell Bioscience Holdings Ltd. (RGC) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Regencell Bioscience Holdings Ltd. (RGC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Regencell Bioscience Holdings Ltd. (RGC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Regencell Bioscience Holdings Ltd. (RGC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Regencell Bioscience Holdings Ltd (RGC) has a current Price-to-Book (P/B) ratio of 2089.95. Compared to its 3-year average P/B ratio of 364.61 , the current P/B ratio is approximately 473.20% higher. Relative to its 5-year average P/B ratio of 239.72, the current P/B ratio is about 771.84% higher. Regencell Bioscience Holdings Ltd (RGC) has a Forward Free Cash Flow (FCF) yield of approximately -0.03%. Compared to its 3-year average FCF yield of -1.25%, the current FCF yield is approximately -97.42% lower. Relative to its 5-year average FCF yield of -0.92% , the current FCF yield is about -96.49% lower.
2089.95
P/B
Median3y
364.61
Median5y
239.72
-0.03
FCF Yield
Median3y
-1.25
Median5y
-0.92
Competitors Valuation Multiple
The average P/S ratio for RGC's competitors is 22.41, providing a benchmark for relative valuation. Regencell Bioscience Holdings Ltd Corp (RGC) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RGC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RGC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Regencell Bioscience Holdings Ltd (RGC) currently overvalued or undervalued?
Regencell Bioscience Holdings Ltd (RGC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between to according to relative valuation methord.
What is Regencell Bioscience Holdings Ltd (RGC) fair value?
RGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between to according to relative valuation methord.
How does RGC's valuation metrics compare to the industry average?
The average P/S ratio for RGC's competitors is 22.41, providing a benchmark for relative valuation. Regencell Bioscience Holdings Ltd Corp (RGC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Regencell Bioscience Holdings Ltd (RGC) as of Jan 08 2026?
As of Jan 08 2026, Regencell Bioscience Holdings Ltd (RGC) has a P/B ratio of 2089.95. This indicates that the market values RGC at 2089.95 times its book value.
What is the current FCF Yield for Regencell Bioscience Holdings Ltd (RGC) as of Jan 08 2026?
As of Jan 08 2026, Regencell Bioscience Holdings Ltd (RGC) has a FCF Yield of -0.03%. This means that for every dollar of Regencell Bioscience Holdings Ltd’s market capitalization, the company generates -0.03 cents in free cash flow.
What is the current Forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC) as of Jan 08 2026?
As of Jan 08 2026, Regencell Bioscience Holdings Ltd (RGC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Regencell Bioscience Holdings Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Regencell Bioscience Holdings Ltd (RGC) as of Jan 08 2026?
As of Jan 08 2026, Regencell Bioscience Holdings Ltd (RGC) has a Forward P/S ratio of 0.00. This means the market is valuing RGC at $0.00 for every dollar of expected revenue over the next 12 months.